Human embryonic stem cells (hESCs) in the treatment of emphysematous COPD: a case report

Geeta Shroff
NutechMediworld, New Delhi, India

Correspondence
Geeta Shroff, NutechMediworld, H-8, Green Park Extension, New Delhi-110016, India.
Tel: +91 11 26180039; Fax: +91 11 2656 0089; E-mail: geetashroff@hotmail.com

Funding Information
No sources of funding were declared for this study.

Received: 26 February 2015; Revised: 4 May 2015; Accepted: 13 May 2015

Clinical Case Reports 2015; 3(7): 632–634
doi: 10.1002/ccr3.310

Introduction
Emphysema is a lung disease [1] that results in narrowing of the small airways and breakdown of the lung tissues. It is due to long-term exposure of irritants like inhaling of cigarette smoke, and other toxic particles that cause lung inflammation. Emphysema is a phenotype of COPD [2] and is amongst the leading cause of deaths in most of the countries [3].

Emphysema is categorized as centriacinar emphysema, panacinar emphysema, and distal acinar emphysema. The connection among these subtypes of emphysema’s is yet to be clarified [4]. The panacinar emphysema shows higher compliance with lungs then the centriacinar emphysema [5]. It occurs more commonly in people who smoke heavily [6].

There is no effective cure for COPD. Treatments like methylxanthines [7], long-term oxygen therapy, corticosteroids, and bronchodilators are used as a conventional therapy. But long-term usage of these treatments increases the risk of pneumonia, arrhythmia, and fractures [3, 8].

Previous studies have shown that cell-based therapies have a potential for lung repair and rehabilitation of lungs after injury [9]. Cell-based therapies play an important role and reduce both alveolar damage and inflammation of the airways [10].

Key Clinical Message
Emphysema results in narrowing of the small airways due to inhaling of cigarette smoke and other noxious particles. Oxygen therapy, corticosteroids, and bronchodilators increase the risk of pneumonia, arrhythmia, and fractures in long term. Therapy with human embryonic stem cells resulted in improved symptoms of a patient with emphysema.

Keywords
COPD, emphysema, human embryonic stem cell therapy.
through intravenous route twice daily for 7 days. He was also nebulized with hESCs suspended in normal saline. The treatment phases were separated by a gap phase of 4–6 months.

Case Presentation

A 52-year-old male was admitted at the Nutech Mediworld on 6 August, 2012 with chief complaints of shortness of breath, pain radiating to the neck, increased cough and wheezing especially at night and after getting up from sleep for the past 9 months. The patient and his wife noticed that he had increased shortness of breath after mild physical exertion (like walking). A visit to a local physician revealed that he had emphysema COPD with not much hope of cure, and only symptomatic treatment was given.

The patient was a heavy smoker since last 30 years and drank alcohol frequently. The family history of patient revealed that the patient’s father died of carcinoma of the lungs and his mother died of stomach cancer.

The first contrast-enhanced computed tomography (CEST) performed on 06 August, 12 showed paraseptal and panacinar emphysematous changes in bilateral lung fields with flattening of the diaphragm.

On examination of the central nervous system (CNS) and other parameters, the patient was clinically normal. The patient had no organomegaly and the bowel sample was normal. The patient was conscious, alert, well oriented to time and with fair nutritional status.

The patient was given hESC therapy as a primary treatment at our facility. After 101 days of the hESC therapy, the patient showed an improvement in symptoms like absence of cough and phlegm. His sleeping and overall stamina also improved. A CEST of chest performed after the therapy on 25 September, 2012 showed paraseptal emphysematous changes in bilateral upper lobes and rest of parenchyma appeared normal. He was also able to completely quit smoking during his stay at our facility.

On his last follow-up on (2014, November), he did not report cough, phlegm, or wheezing, was able to work full time and to walk long distances.

Discussion

In the present study, an improvement in cough, phlegm, and overall stamina was observed in a patient with emphysema after hESC therapy. CEST performed after the therapy showed normal parenchyma of the lungs. No adverse events (AEs) were seen in patient following the treatment with hESC.

Previous studies have shown that there is a potential in cell lines to consummate multipotent lung progenitors in association with combined growth factors and novel markers (LIFRx and NRPI) [15]. The mesenchymal stem cells (MSCs) release chemokines, cytokines, and growth factors to the injury site and act as migratory cues. These cues influence selectins and result in activation of integrins on the stem cell surface. This permits the stem cells to interact, adhere, and transmigrate through endothelium [16]. A study by Lee and colleagues stated that MSCs can mitigate the inflammatory and lung injury in isolated perfused human lungs. MSCs released anti-inflammatory mediators to the injury site and repair the damaged cells [17]. The study showed a base for therapeutic use of hESCs in a variety of lung diseases. So, we might possibly explain that hESCs used in our study also rely on the same mechanism of action. We assume that our hESCs also penetrate across the parenchyma and migrate to the affected region. These cells then differentiated into lung epithelial cells and replaced the damaged cells. The use of stem cells is restricted due to the fear of AEs as teratoma formation and immune rejection. In our patient, we have not observed any AE. We have already established the safety of hESC therapy in patients with terminal/incurable conditions [18].

No study till date assessed the therapeutic potential of hESCs in the treatment of patients with emphysema. This is the first study to report the use of hESCs as therapy in lung repair. The patient had an uneventful recovery. Our patient showed remarkable clinical improvement and an improved quality of life. Though he quit smoking, but improvement observed in the patient cannot be justified for his improvement that was observed in a very small span of time. He had been a heavy smoker for last 30 years and his stay at our facility was about 3.5 months only. It has also been reported previously that after smoking cessation, the inflammation, apoptosis, and oxidative stress can remain and sustain to contribute to COPD [19]. There is an ethical concern regarding the use of hESCs like using fertilized embryo, misuse of cells and use in experimental purposes. The fertilized ovum for the present hESCs was donated willingly by a woman undergoing IVF and she was cognizant that it would be used for experimental and research purpose. Moreover, we have used this therapy on patients with incurable conditions and nothing can be more unethical than denying a ray of hope to the patients who have tried all treatments and still shown no improvement. However, we were not able to perform bronchoalveolar lavage sample examination of the patient before and after the treatment. Future well-designed studies can further clarify the role of hESC therapy in patients with emphysematous lung disease.

Conclusion

Therefore, it is summarized that hESCs showed good therapeutic potential in the treatment of patients with...
emphysematous COPD. Clinical trials reveal that cell-based therapies have a potential for lung repair and rehabilitation of lungs after injury. However, more clinical trials and follow-up studies are needed to prove the long-term efficacy and safety of hESCs in the treatment of patients with emphysema COPD.

Acknowledgments

The author acknowledges all the doctors, staff, and patients of the Nutech Mediworld. The author also acknowledges Knowledge Isotopes Pvt. Ltd. (www.knowledgesisotopes.com), for the Medical writing assistance.

Conflict of Interest

Authors have no conflict of interest.

References

1. NIH Available at: http://wwwnhlinnihgov/health/health-topics/topics/copd; accessed on 27 January, 2015.
2. Meena, M., R. Dixit, M. Singh, J. K. Samaria, and S. Kumar. 2014. Surgical and bronchoscopic lung volume reduction in chronic obstructive pulmonary disease. Pulm. Med. 2014:757016.
3. Vestbo, J., S. S. Hurd, A. G. Agusti, P. W. Jones, C. Vogelmeier, A. Anzueto, et al. 2013. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 187:347–365.
4. Takahashi, M., J. Fukuoka, N. Nitta, R. Takazakura, Y. Nagatani, Y. Murakami, et al. 2008. Imaging of pulmonary emphysema: a pictorial review. Int. J. Chron. Obstruct. Pulmon. Dis. 3:193–204.
5. Saetta, M., W. D. Kim, J. L. Izquierdo, H. Ghezzo, and M. G. Cosio. 1994. Extent of centrilobular and panacinar emphysema in smokers' lungs: pathological and mechanical implications. Eur. Respir. J. 7:664–671.
6. Mittler, R., and E. Tel-Or. 1991. Oxidative stress responses in the unicellular cyanobacterium Synechococcus PCC 7942. Free Radic. Res. Commun. 12–13(Pt 2):845–850.
7. Shukla, D., S. Chakraborty, S. Singh, and B. Mishra. 2009. Doxofylline: a promising methylxanthine derivative for the treatment of asthma and chronic obstructive pulmonary disease. Expert Opin. Pharmacother. 10:2343–2356.
8. Wilchesky, M., P. Ernst, J. M. Brophy, R. W. Platt, and S. Suissa. 2012. Bronchodilator use and the risk of arrhythmia in COPD: part 1: Saskatchewan cohort study. Chest 142:298–304.
9. Sueblinvong, V., and D. J. Weiss. 2009. Cell therapy approaches for lung diseases: current status. Curr. Opin. Pharmacol. 9(3):268–273.
10. Petty, T. L. 2006. The history of COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 1:3–14.
11. Shroff, G., A. Gupta, and J. Barthakur. 2014. Therapeutic potential of human embryonic stem cell transplantation in patients with cerebral palsy. J. Transl. Med. 12:318.
12. Shroff, G., and L. Das. 2014. Human embryonic stem cell therapy in cerebral palsy children with cortical visual impairment: a case series of 40 patients. J. Cell Sci. Ther. 5:189.
13. Shroff, G.. 2015. A novel approach of human embryonic stem cell therapy in treatment of Friedrich’s Ataxia. Int. J. Case Rep. Images 6:261–266.
14. House of Lords SATSC. Available from http://wwwparliamentuk/documents/lords-committees/science-technology/RegenerativeMedicine/RegenMedpdf; accessed on 29 January, 2015.
15. McIntyre, B. A., C. Alev, R. Mechael, K. R. Salci, J. B. Lee, A. Fiebig-Comyn, et al. 2014. Expansive generation of functional airway epithelium from human embryonic stem cells. Stem Cells Transl. Med. 3:7–17.
16. Karp, J. M., and G. S. Leng Teo 2009. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell 4:206–216.
17. Lee, J. W., X. Fang, N. Gupta, V. Serikov, and M. A. Matthay. 2009. Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung. Proc. Natl Acad. Sci. USA 106:16357–16362.
18. Shroff, G., and J. Barthakur. 2015. Safety of human embryonic stem cells in patients with terminal condition. Ann. Neurosci. 22:132–138.
19. Jin, Z., X. Pan, K. Zhou, H. Bi, L. Wang, L. Yu, et al. 2015. Biological effects and mechanisms of action of mesenchymal stem cell therapy in chronic obstructive pulmonary disease. J. Int. Med. Res. 43:304–310.